Charles River Laboratories CRL Bearer biological assets

Other financials

Revenue$995.8M+1.2%

Gross profit$349.0M-3.5%

Operating income$119.9M+60.6%

Net income-$14.8M-158%

EPS (diluted)-$0.30-160%

Cash & equivalents$198.2M-14.5%

Total debt$3.1B+1.9%

Total equity$2.9B-7.9%

Total assets$7.7B+2.0%

Operating cash flow$41.1M-76.1%

CapEx$55.9M-5.8%

Free cash flow-$14.8M-113%

Market cap$8.91B+10.3%

Enterprise value$11.79B+8.5%

P/S2.2×+0.2×

Gross margin84.7%—

Operating margin13%-2.4pp

Net margin-4.6%—

FCF margin9.7%-4.3pp

Return on equity-6%—

Debt / equity1×+0.1×

Current ratio1.4×-0.1×

Reported directly by Charles River Laboratories in its filing.

Tagged under the XBRL concept crl:BearerBiologicalAssetsNoncurrent.

The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Charles River Laboratories's bearer biological assets?: Charles River Laboratories (CRL) reported bearer biological assets of $406.25M in Q1 2026.